Write a Comment
4 Comments
Tivicay (dolutegravir) taken as monotherapy is more efficient than truvada lowering viremy and shows the highest barrier to resistance than any other antiviral. the future first line therapy will be based on tivicay plus only a second, tollerable, drugs (like lamivudine or rilpivirine). no more need for tenofovir (TAF or TDF)... just wait the end of the ongoing trials about the simplified therapy...
Safe, safer, safest, it seems semantics is now playing a huge role in shlepping pharmaceuticals and in this instance TAF. Only time will tell if it is indeed "safer" than it's predecessor, which in my personal experience was poisonous to nerves, kidneys, liver and list goes on-as per Gilled's own research (read the product's literature). We desperately need a better class of drugs than NRTIs which, through their effects on mitochondrial homeostasis and ROS, lead to their toxicities.
I still would not take this s#%^t, as the other version of Truvada ruined my kidneys!
Matias47
Why is it not for PrEP? It’s safer. There’s already a class action suit against Truvada for suppressing the extent of the bone and kidney damage information - I fear that’s going to grow the more old Truvada only is used for PrEP.
June 11, 2018